FDA update on ABBV 951 (foscarbidopa/fFoslevodopa) for the treatment of motor fluctuations in adults with advanced Parkinson's disease
AbbVie announced it received a Complete Response Letter (CRL) from the FDA for the New Drug Application (NDA) for ABBV 951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in adults with advanced Parkinson's disease
In its letter, the FDA cited observations that were identified during inspection of a third-party manufacturer listed in the New Drug Application (NDA). The inspection at the facility did not involve ABBV 951 or any AbbVie medicine.
"There remains a tremendous unmet need for treatment options for patients living with advanced Parkinson's disease in the United States," said Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, AbbVie. "We are focused on working with the FDA to bring this important therapy to patients as soon as possible."
The CRL does not identify any issues related to the safety, efficacy or labeling of ABBV 951, including the device. The CRL does not request that AbbVie conduct additional efficacy and safety trials related to the drug or device-related testing.
About ABBV 951: ABBV 951 (foscarbidopa/foslevodopa) is a solution of carbidopa and levodopa prodrugs for 24-hour continuous subcutaneous infusion for the treatment of motor fluctuations in adults with advanced Parkinson's disease. ABBV 951 has been approved in 34 countries and over 2,100 patients worldwide have started treatment. AbbVie continues to work with regulatory authorities around the world to bring ABBV 951 to people living with advanced Parkinson's disease.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins